RESEARCH GROUPS

Psychiatry, Mental Health and Addictions

Overview

Team

Publications

Patents

Dissemination

61

Number of publications

70.49
%

% Q1

55.74
%

% D1

40.98
%

% Leadership

60.00
%

% Female Leadership

5.12

CROWN (2021-2025)

31.54
%

HCP10% (2021-2025)

78.69
%

% Open access

60.66
%

% International Collaboration

22

Highly cited papers / HCP 1% (2021-2025)

11

Publications in high-IF journals with high Altmetric scores

23

Number of Ongoing Projectes (total)

2

International ongoing projects

5

Number of New projects (total)

0

International new projects

12

Number of Active clinical Trials

4

Number of New Clinical Trials

1

Number of Theses

The Psychiatry, Mental Health and Addictions Group is a multidisciplinary research team composed of psychiatrists, clinical pharmacologists, psychologists, mathematicians, geneticists, and biotechnologists, with extensive experience in both clinical care and research on mental disorders across the lifespan. These include attention-deficit/hyperactivity disorder, autism spectrum disorder, borderline personality disorder, substance use disorders, early psychosis and bipolar disorder. It benefits from sustained and overlapping competitive funding from national and international public institutions (including H2020 and NIH programmes), as well as private foundations. The group actively collaborates within multiple national and international consortia and has produced a strong scientific output published in high-impact journals such as Science, Nature Genetics, Nature, Cell, The Lancet Psychiatry, Molecular Psychiatry, among others. The group currently comprises a total of 41 researchers.

CORE/MISSIONS

  • AI, Data, Imaging & Digital Health
  • Environmental & Public Health
  • Innovative & Advanced Therapies

PROGRAMS

  • Robotic Surgery & Simulation
  • Woman, Gender & Diversity Perspective in Health Research
Group Leader

Josep Antoni Ramos-Quiroga

Principal Investigator (PI)

Josep Antoni Ramos-Quiroga and Marta Ribasés Haro

Researchers

Josep Antoni Ramos Quiroga, Marta Ribasés, María Soler, Silvia Amoretti, Lara Grau, Constanza Daigre, Raquel Vidal, Silvia Alemany, Marc Ferrer, Marta Quesada, Natalia Calvo, Francisco Collazos, Gara Arteaga, Judit Cabana, Christian Fradeuilhe, Gemma Nieva, Amanda Rodriguez, Laura Gisbert, Pilar Lusilla, Elena Ros, Sara Fidel-Kinori, Vanesa Richarte, Álex González, Montse Corrales, Jorge Lugo, Dolores Braquehais, Gemma Español, Raúl Felipe Palma-Álvarez

PhD Students

Natalia Llonga, Uxue Zubizarreta, Pau Carabí, Manuel Donato Rodriguez, Matea Sköjo, Anna Beneria

Lab Technicians

Valeria Macias

O'Connell KS, Koromina M, van der Veen T, Boltz T, David FS, Yang JMK, Lin KH, Wang X, Coleman JRI, Mitchell BL, McGrouther CC, Rangan AV, Lind PA, Koch E, Harder A, Parker N, Bendl J, Adorjan K, Agerbo E, Albani D, Alemany S, Alliey-Rodriguez N, Als TD, Andlauer TFM, Antoniou A, Ask H, Bass N, Bauer M, Beins EC, Bigdeli TB, Pedersen CB, Boks MP, Børte S, Bosch R, Brum M, Brumpton BM, Brunkhorst-Kanaan N, Budde M, Bybjerg-Grauholm J, Byerley W, Cabana-Domínguez J, Cairns MJ, Carpiniello B, Casas M, Cervantes P, Chatzinakos C, Chen HC, Clarence T, Clarke TK, Claus I, Coombes B, Corfield EC, Cruceanu C, Cuellar-Barboza A, Czerski PM, Dafnas K, Dale AM, Dalkner N, Degenhardt F, DePaulo JR, Djurovic S, Drange OK, Escott-Price V, Fanous AH, Fellendorf FT, Ferrier IN, Forty L, Frank J, Frei O, Freimer NB, Fullard JF, Garnham J, Gizer IR, Gordon SD, Gordon-Smith K, Greenwood TA, Grove J, Guzman-Parra J, Ha TH, Hahn T, Haraldsson M, Hautzinger M, Havdahl A, Heilbronner U, Hellgren D, Herms S, Hickie IB, Hoffmann P, Holmans PA, Huang MC, Ikeda M, Jamain S, Johnson JS, Jonsson L, Kalman JL, Kamatani Y, Kennedy JL, Kim E, Kim J, Kittel-Schneider S, Knowles JA, Kogevinas M, Kranz TM, Krebs K, Kushner SA, Lavebratt C, Lawrence J, Leber M, Lee HJ, Liao C, Lucae S, Lundberg M, MacIntyre DJ, Maier W, Maihofer AX, Malaspina D, Manchia M, Maratou E, Martinsson L, Mattheisen M, McGregor NW, McInnis MG, McKay JD, Medeiros H, Meyer-Lindenberg A, Millischer V, Morris DW, Moutsatsou P, Mühleisen TW, O'Donovan C, Olsen CM, Panagiotaropoulou G, Papiol S, Pardiñas AF, Park HY, Perry A, Pfennig A, Pisanu C, Potash JB, Quested D, Rapaport MH, Regeer EJ, Rice JP, Rivera M, Schulte EC, Senner F, Shadrin A, Shilling PD, Sigurdsson E, Sindermann L, Sirignano L, Siskind D, Slaney C, Sloofman LG, Smeland OB, Smith DJ, Sobell JL, Soler Artigas M, Stein DJ, Stein F, Su MH, Sung H, Świątkowska B, Terao C, Tesfaye M, Tesli M, Thorgeirsson TE, Thorp JG, Toma C, Tondo L, Tooney PA, Tsai SJ, Tsermpini EE, Vawter MP, Vedder H, Vreeker A, Walters JTR, Winsvold BS, Witt SH, Won HH, Ye R, Young AH, Zandi PP, Zillich L; 23andMe Research Team; Adolfsson R, Alda M, Alfredsson L, Backlund L, Baune BT, Bellivier F, Bengesser S, Berrettini WH, Biernacka JM, Boehnke M, Børglum AD, Breen G, Carr VJ, Catts S, Cichon S, Corvin A, Craddock N, Dannlowski U, Dikeos D, Etain B, Ferentinos P, Frye M, Fullerton JM, Gawlik M, Gershon ES, Goes FS, Green MJ, Grigoroiu-Serbanescu M, Hauser J, Henskens FA, Hjerling-Leffler J, Hougaard DM, Hveem K, Iwata N, Jones I, Jones LA, Kahn RS, Kelsoe JR, Kircher T, Kirov G, Kuo PH, Landén M, Leboyer M, Li QS, Lissowska J, Lochner C, Loughland C, Luykx JJ, Martin NG, Mathews CA, Mayoral F, McElroy SL, McIntosh AM, McMahon FJ, Medland SE, Melle I, Milani L, Mitchell PB, Morken G, Mors O, Mortensen PB, Müller-Myhsok B, Myers RM, Myung W, Neale BM, Nievergelt CM, Nordentoft M, Nöthen MM, Nurnberger JI, O'Donovan MC, Oedegaard KJ, Olsson T, Owen MJ, Paciga SA, Pantelis C, Pato CN, Pato MT, Patrinos GP, Pawlak JM, Ramos-Quiroga JA, Reif A, Reininghaus EZ, Ribasés M, Rietschel M, Ripke S, Rouleau GA, Roussos P, Saito T, Schall U, Schalling M, Schofield PR, Schulze TG, Scott LJ, Scott RJ, Serretti A, Smoller JW, Squassina A, Stahl EA, Stefansson H, Stefansson K, Stordal E, Streit F, Sullivan PF, Turecki G, Vaaler AE, Vieta E, Vincent JB, Waldman ID, Weickert CS, Weickert TW, Werge T, Whiteman DC, Zwart JA, Edenberg HJ, McQuillin A, Forstner AJ, Mullins N, Di Florio A, Ophoff RA, Andreassen OA; Bipolar Disorder Working Group of the Psychiatric Genomics Consortium.
Genomics yields biological and phenotypic insights into bipolar disorder.
Nature. 2025 Mar;639(8056):968-975.
DOI: 10.1038/s41586-024-08468-9
IF: 50,5

Ferrer M, Richarte V, Gisbert L, Xaus J, Gutierrez S, Arevalo MI, Ropacki M, Bullock R, Buesa C, Ramos-Quiroga JA.
REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders.
Psychiatry and Clinical Neurosciences. 2025 May;79(5):257-265.
DOI: 10.1111/pcn.13800
IF: 11.9

Cabana-Domínguez J, Bosch R, Soler Artigas M, Alemany S, Llonga N, Vilar-Ribó L, Carabí-Gassol P, Arribas L, Macias-Chimborazo V, Español-Martín G, Del Castillo C, Martínez L, Pagerols M, Pagespetit È, Prat R, Puigbó J, Ramos-Quiroga JA, Casas M, Ribasés M.
Dissecting the polygenic contribution of attention-deficit/hyperactivity disorder and autism spectrum disorder on school performance by their relationship with educational attainment.
Molecular Psychiatry. 2024 Nov;29(11):3503-3515.
DOI: 10.1038/s41380-024-02582-w
IF: 13.4

Arteaga-Henríquez G, Ramos-Sayalero C, Ibañez-Jimenez P, Karina Rosales-Ortiz S, Kilencz T, Schiweck C, Schnorr I, Siegl A, Arias-Vasquez A, Bitter I, Fadeuilhe C, Ferrer M, Lavebratt C, Matura S, Reif A, Réthelyi JM, Richarte V, Rommelse N, Ramos-Quiroga JA.
Efficacy of a symbiotic in the management of adults with Attention-Deficit and Hyperactivity Disorder and/or Borderline Personality Disorder and high levels of irritability: Results from a multicenter, randomized, placebo-controlled, “basket” trial.
Brain, Behavior, and Immunity 2024 Aug;120:360-371.
DOI: 10.1016/j.bbi.2024.06.012
IF: 15.1

Cabana-Domínguez J, Llonga N, Arribas L, Alemany S, Vilar-Ribó L, Demontis D, Fadeuilhe C, Corrales M, Richarte V, Børglum AD, Ramos-Quiroga JA, Soler Artigas M, Ribasés M.
Transcriptomic risk scores for attention deficit/hyperactivity disorder.
Molecular Psychiatry. 2023 Aug;28(8):3493-3502.
DOI: 10.1038/s41380-023-02200-1
IF: 13.4

The EU-PEARL Integrated Platform Trial for Depression
Principal Investigator: J.A. Ramos-Quiroga
Agency: Welcome Trust Foundation
Funding: 13,677,960€ (FOR VHIR: 364,990€)
Period: 01/12/2024 – 30/11/2028

Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients (TIMESPAN)
Principal Investigator: J.A. Ramos-Quiroga
Agency: European Commission
Funding: 499,989.25 €
Period: 01/03/2021 – 03/03/2025 (extension period after December 2026)

DynAMoND – Dynamics of Affective Modulation in Neurodevelopmental Disorders
Principal Investigator: J.A. Ramos-Quiroga
Agency: NEURON / Instituto de Salud Carlos III
Funding: 174,845€
Period: 01/03/2022 – 04/03/2026

DISCOvERIE: Development, diagnosis and prevention of gender-related Somatic and mental COmorbiditiEs in iRrItable bowel syndrome in Europe
Principal Investigator: Dr. Ramos-Quiroga
Agency: European Comission.
Funding: 779,490€
Period: 01/01/2020 - 31/12/2024 (extension up to December 2025)

Multikingdom Gut Microbiota Profiling and Plasma lnflammatory Markers in Adults with Attention-Deficit/Hyperactivity Disorder (Gut-MIND)
Principal Investigator: Christian Fadeuilhe
Agency: Instituto de Salud Carlos III
Funding: 270,423€
Period: 2025-2028

Methods of Treating Borderline Personality Disorder
Priority Number: PCT/EP2020/057803
Priority Date: 2020
Applicants: Oryzon Genomics, S.A.

Methods of Treating Attention Deficit Hyperactivity Disorder Using KDM1A Inhibitors Such as the Compound Vafidemstat
Priority Number: PCT/EP2020/057800
Priority Date: 2020
Applicants: Oryzon Genomics, S.A.

Vafidemstat for Use in Treating Autism Spectrum Disorders
Priority Number: PCT/EP2020/074602
Priority Date: 2020
Applicants: Oryzon Genomics, S.A.

II CURSO TEÓRICO SOBRE EL ABORDAJE DEL INSOMNIO EN LA SALUD MENTAL
Place: Barcelona
Date: 21-22/03/2025
Brief: Members of our team provided a training session on the most recent advances in insomnia for a multidisciplinary group of healthcare professionals.

PRECEPTORSHIP: MANAGEMENT OF SCHIZOPHRENIA – HOSPITAL UNIVERSITARI VALL D`HEBRON
Place: Barcelona
Date: 09/05/2025
Brief: Members of our team provided a training session on the most recent advances in schizophrenia for a multidisciplinary group of healthcare professionals.